We found no significant difference in the extent of tumor-associated angiogenesis (indicated by CD31) or lymphangiogenesis (indicated by LYVE-1) between CHR-6494-treated and vehicle-treated mice (Fig 4D and 4E). Here, LYVE1 is linked to neoplasm.